# AstraZeneca Plc Forxiga approved in Europe for type-1 diabetes

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-forxiga-approved-in-europe-for-type-1-diabetes/412770508
- Published: 2019-03-25T07:25:46+00:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)),
today announced that The European Commission (EC) has approved Forxiga (dapagliflozin)
for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI
≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite
optimal insulin therapy. This is the first approval of Forxiga for the treatment
of patients with T1D.

Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism,
R&D BioPharmaceuticals, said: “Forxiga is the first oral medicine approved in Europe
as an adjunct to insulin for people living with type-1 diabetes whose glucose levels
are not adequately controlled with insulin alone. We look forward to bringing Forxiga
to a patient population that has not had any approved oral medicines available before.”

The approval is based on data from the Phase III DEPICT clinical programme for Forxiga
in T1D. The short-term (24 week) and long-term (52 week) data from DEPICT-1, along
with the short-term data from DEPICT-2, showed that Forxiga 5mg daily, when given
as an oral adjunct to adjustable insulin in patients with inadequately-controlled
T1D, demonstrated significant and clinically-meaningful reductions from baseline
in average blood glucose levels HbA1c (primary endpoint), weight and total daily
insulin dose (secondary endpoints) at 24 and 52 weeks.1,2,3

The safety profile of Forxiga in these T1D trials was consistent with its well-established
profile in type-2 diabetes (T2D), with the exception of a higher number of diabetic
ketoacidosis (DKA) events in Forxiga-treated patients. DKA is a known complication
for adults with T1D that affects those with T1D more frequently than with T2D. Forxiga
is already indicated as a monotherapy and as part of combination therapy in adults
with T2D to improve glycaemic control, with the additional benefits of weight loss
and blood pressure reduction, as an adjunct to diet and exercise.

Forxiga is currently under regulatory review in Japan and the US for use as an adjunct
treatment to insulin in adults with T1D, with a decision expected in the first and
second half of 2019, respectively.

**About type-1 diabetes**

T1D is a chronic disease in which the pancreas produces little or no insulin. Approximately
five percent of people living with diabetes have type-1. The condition is caused
by an autoimmune reaction that destroys the beta cells in the pancreas which make
insulin.4 Different factors, including genetics and some viruses, may contribute
to type-1 diabetes.5

**About the DEPICT clinical programme**

The DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type
1 Diabetes) clinical trial programme consists of two clinical trials: DEPICT-1 (
NCT02268214) and DEPICT-2 (NCT02460978). DEPICT-1 and DEPICT-2 are 24-week, randomised,
double-blinded, parallel-controlled trials designed to assess the effects of Forxiga
5mg or 10mg on glycaemic control in patients with T1D inadequately controlled by
insulin. All patients were evaluated at week 24 and after a 28-week extension (52
weeks in total). Forxiga 10mg has not been approved for the treatment of T1D.

**About Forxiga**

Forxiga (dapagliflozin) is a first-in-class, oral once-daily selective inhibitor
of human sodium-glucose co-transporter 2 (SGLT2) indicated as both monotherapy and
as part of combination therapy to improve glycaemic control, with the additional
benefits of weight loss and blood pressure reduction, as an adjunct to diet and 
exercise in adults with T2D. Forxiga has a robust clinical trial programme of more
than 35 completed and ongoing Phase IIb/III trials in over 35,000 patients, as well
as more than 1.8 million patient-years’ experience.

**About AstraZeneca in Cardiovascular, Renal & Metabolism (CVRM)**

Cardiovascular, renal and metabolism together form one of AstraZeneca’s main therapy
areas and a key growth driver for the Company. By following the science to understand
more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca
is investing in a portfolio of medicines to protect organs and improve outcomes 
by slowing disease progression, reducing risks and tackling co-morbidities. Our 
ambition is to modify or halt the natural course of CVRM diseases and potentially
regenerate organs and restore function, by continuing to deliver transformative 
science that improves treatment practices and cardiovascular health for millions
of patients worldwide.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on:
